Tag Archives: Pfizer

Pharma Showing Signs of Stability Despite Patent Cliffs

The pharmaceutical market is beginning to show signs of stability, with a review of 30 leading companies highlighting combined revenues of $718.7 billion in 2013, down just 0.2% from 2012, according to GlobalData.
Posted in Deals, Strategy | Also tagged , , , , , | Leave a comment

Is Pfizer Ready for Another Acquisition?

After Pfizer’s aborted acquisition of AstraZeneca, will the drug maker likely approach another company for takeover? This Applied Clinical Trials article discusses some background on Pfizer’s financial history, evaluates its R&D portfolio, and determines whether it is ready for another acquisition attempt. Read more…
Posted in Deals, Strategy | Also tagged , | Leave a comment

Are You Aging Well? Ask Pfizer

I’ve just finished taking Pfizer’s #FOGO (Have A Fear of Getting Old?) test on getold.com. I passed with flying colors. The results assured me that I would have a hell of a time aging during these advancing years and that the last lap of my life would be a breeze. Why? I wonder. Was it […]
Posted in healthcare, Op-Ed, Patient Communication, patient education, social media | Also tagged , | Leave a comment

New "Blockbusters" Will Triple Acute Coronary Syndrome Market

The launch of several drugs with “extraordinary blockbuster potential” will more than triple the acute coronary syndrome (ACS) treatment market, from $12.3 billion in 2013 to $43.4 billion by 2023, according to research and consulting firm GlobalData.
Posted in Global, Strategy | Also tagged , , , , , , | Leave a comment

The Rx Firm Tax Exodus: Is Something Wrong with the U.S. System?

As I read the latest reports of yet another big US Rx firm, this time AbbVie, trying to pull off a “tax inversion” takeover of the Irish-based Shire, I couldn’t help but wonder, what the heck is going on here? Right now, it feels like most major US corporations, especially pharmas, are literally running away […]
Posted in Deals, Europe, Global, Guest Blog, Legal, Op-Ed, Strategy | Also tagged , , , , , | Leave a comment
  • Categories

  • Meta